Gold loses its glitter; some sheen for silver
The Iran-Israel conflict triggered some buying interest during middle of June, but it fizzled out soon. Lack of any meaningful trigger kept the gold price in check in June.
As a result, Comex gold closed almost unchanged at $3,315 at the end of June, representing a 0.06% fall. The performance of Comex silver was relatively better last month with the white metal gaining 9.8% to settle at $36.3 at the end of June.
Global markets lack sheen
Mirroring the trend in the global markets, MCX Gold price closed 0.2% lower to settle at ₹96,111 per 10-grams at the end of June.
MCX silver posted a much better performance, recording a 8.2% gain in June to settle at ₹1,06,325 per kilogram.
As anticipated last month, the price of Comex gold remained range bound and could not breakout out of the broad range of $3,120-$3,450 zone.
As observed last month, only a breakout from this zone would set the tone for the next big move. Until then, expect volatile price action within the $3,120-$3,450 zone.
Relative outperformance
After several months, silver displayed signs of relative outperformance in comparison to gold. Comex silver price managed to breakout above the upper end of the prior range of $30.5-$34.5. As mentioned last month, this breakout imparted upside momentum and the price scaled a high of $37.45 on June 18.
The short-term outlook for Comex silver is positive and the price could head to the next target zone at $39.5-$40.5. A fall below $34 would invalidate this positive outlook.
MCX gold was confined within the broad range of ₹91,000-₹1,00,100. A breakout from this range would trigger a strong move in the direction of the breakout. Above ₹1,02,000, the price could head to the next target zone of ₹1,08,000-₹1,10,000. On the other hand, a breach of the lower end of the range of ₹91,000 would push gold price lower to the next support zone at ₹85,500-₹86,000.
MCX silver price has settled comfortably above the psychological ₹1,00,000 mark since the beginning of June. The silver price has also crossed the upper end of the prior trading range, which is a sign of strength. The short-term outlook for MCX Silver is positive and the price could head to the next target at ₹1,16,500-₹1,18,500 zone. Only a fall below ₹1,01,500 would invalidate the positive outlook.
To summarise, gold is likely to remain range bound but silver looks relatively strong and could inch higher in the short-term.
(The author is a Chennai-based analyst / trader. The views and opinion featured in this column is based on an analysis of short-term price movement in gold and silver futures at COMEX & Multi Commodity Exchange of India. This is not meant to be a trading or investment advice.)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
20 minutes ago
- Business Standard
Partners Group to acquire majority stake in Infinity Fincorp for ₹1,950 cr
Infinity Fincorp Solutions, a leading non-bank lender, has signed a share purchase and subscription agreement with Partners Group, as part of which the latter will acquire a significant majority stake in the business, the company said in an official statement. The transaction is subject to regulatory approval. The total deal is worth ₹1,950 crore (approximately $230 million), including a primary issuance of ₹600 crore (around $70 million) of shares, as well as a secondary purchase of shares from Indium IV (Mauritius) Holdings Ltd, a fund managed by Global Opportunity Advisors (Mauritius) Ltd and advised by True North Managers LLP, along with other shareholders. Jungle Ventures, an existing investor, has also participated in the funding round. Avendus Capital acted as the exclusive financial advisor to both Infinity and Indium IV (Mauritius) Holdings for this transaction. Supporting MSMEs across India Mumbai-based Infinity focuses on lending to unbanked and under-banked micro, small and medium enterprises (MSMEs) across India, providing them with secured, customised loans. The sector's credit gap is estimated to be ₹33 trillion and is increasing by about 16 per cent annually. Infinity manages more than ₹1,200 crore (roughly $140 million) in assets and serves about 50,000 customers through more than 120 branches across eight states, mainly in agriculture, trading and manufacturing sectors in smaller towns and cities. The fresh capital raised will be used to accelerate branch expansion and invest in technology that will improve customer experience and onboarding. Strengthening operations and expanding reach 'We welcome Partners Group and intend on leveraging their operational expertise to further broad-base our mission of serving the Indian MSME sector,' said Shrikant Ravalkar, founder, managing director (MD) and chief executive officer (CEO) of Infinity, in a statement. 'We are dedicated to empowering entrepreneurs and business owners across Tier 3 towns in India, through flexible, need-based lending solutions that are designed to create long-term impact.' In a media statement, Vageesh Gupta, MD (private equity) at Partners Group, said: 'The MSME segment contributes a significant share of national GDP and we expect demand for credit will continue to rise. We believe non-bank lenders such as Infinity have advantages in catering to these enterprises due to their highly specialised operations that are better suited to providing customised solutions.'
&w=3840&q=100)
Business Standard
21 minutes ago
- Business Standard
F&O turnover declines 21% as market sees impact of Jane Street ban
On the first expiry of Nifty weekly contracts since the ban on US-based high-frequency trader Jane Street, the total turnover on the National Stock Exchange (NSE) dropped 21 per cent compared to the previous expiry day. Index options turnover on a notional basis slipped to ₹472.5 trillion on Thursday, down from ₹601 trillion on July 3 – the day before Jane Street was barred by the market regulator, the Securities and Exchange Board of India (Sebi). In terms of the number of index options contracts traded at 247 million on Thursday were the lowest in three months. Several market participants had raised concerns that the restriction on proprietary trading firms' activities could dent volumes. They said a clearer picture would emerge in a few weeks. HFTs (high-frequency traders) can account for as much as 60 per cent of the derivatives turnover, with a strong hold in options. Another market player highlighted that the markets may see healthier trends in the long run by reinstating confidence among smaller investors and reducing dependence on a single entity. From a peak of around ₹537 trillion in September, the average daily F&O turnover in the equities segment fell 35 per cent to around ₹346 trillion in June, driven by Sebi's tightened regulations to curb manipulation and excessive speculation.
&w=3840&q=100)
Business Standard
23 minutes ago
- Business Standard
Glenmark arm IGI licenses cancer drug to AbbVie for upfront $700 million
In what can be called a landmark deal for Indian pharma and research, IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc. (IGI), signed an exclusive licensing agreement with US-based AbbVie for its oncology and autoimmune diseases asset ISB 2001. The deal includes an upfront payment of $700 million (₹6,000 crore) and milestone-based payments of up to $1.2 billion (close to ₹10,000 crore). ISB 2001, an investigational asset, has been developed using IGI's proprietary BEAT protein platform for oncology and autoimmune diseases. The US Food and Drug Administration granted ISB 2001 orphan drug designation in July 2023 and fast-track designation in May 2025 for the treatment of relapsed or refractory myeloma patients. The Phase-1 trial in human studies is underway, and dose escalations are currently being tested. The company believes that due to its mechanism of action, ISB 2001 could potentially be a viable therapeutic option for various autoimmune indications. Glenmark shares have risen 38 per cent in the last three months and, on Thursday, touched a fresh all-time high of ₹1,919 apiece. IGI is a wholly owned subsidiary of Mumbai-headquartered Glenmark. Speaking to reporters, Chairman and Managing Director Glenn Saldanha said, 'This deal puts India on the world map. There is no parallel to ₹6,000 crore upfront payment.' He added that the deal ranks among the top out-licensing deals in the antibody space globally. Notable recent deals include 3SBio Inc. and Pfizer's $6 billion licensing deal for global rights (excluding China) to develop, manufacture, and commercialize 3SBio's bispecific antibody SSGJ-707. This deal involved an upfront payment of $1.2 billion to 3SBio. Roopal Thakkar, MD, Executive Vice-President, Research and Development, and Chief Scientific Officer at AbbVie, said, 'Multispecifics, including trispecific antibodies, represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously.' Glenmark expects the molecule to transform the multiple myeloma space, which could become a $50 billion market by 2030. The asset may take another 4-5 years to be commercialized if timelines are met. ISB 2001's competitors include Pfizer and J&J's already launched drugs for multiple myeloma. Looking ahead, IGI is likely to pursue an IPO, but nothing is immediately on the cards, Saldanha said. The research arm is self-funded for at least the next three to four years, as it uses $70 million annually. Saldanha also mentioned that the ₹6,000 crore would definitely be used to fund IGI's pipeline of investigational assets, with some amount to be paid as a dividend to Glenmark shareholders. Glenmark had a net debt of ₹400 crore before the deal, and Saldanha stated they would now be net-cash. Saldanha has fought a long battle to pursue his ambitions around innovation and has already tasted success with several key partnerships forged with players like Almirall and Astria for innovation assets. Glenmark has had its tryst with managing R&D spending, debt, and cash flows over the years. In 2019, Glenmark spun off its research unit into a separate subsidiary to de-risk its investments, reduce debt, and improve focus on the core business. Earlier, cash flows from the base business were deployed in the high-risk innovation programme, which many analysts had felt was a drag on shareholder value. Motilal Oswal analyst Tushar Manudhane noted recently that Glenmark is on track to optimise R&D spending on its innovation assets. From 8 per cent (₹800 crore) of total sales in FY19, the company reduced innovation R&D spend to 4.5 per cent (₹600 crore) in FY24, and further to 3.5 per cent of sales in 9MFY25, Manudhane said. IGI had entered into an exclusive global licensing agreement for another innovation asset, ISB 880 in autoimmune diseases, with Spanish firm Almirall in December 2021. Glenmark received $320 million for upfront payment, development, regulatory, and sales milestone payments, plus tiered royalties on global sales. In another major deal, IGI entered an exclusive global licensing agreement for ISB 830 and its follow-on ISB 830-X8 (monoclonal antibody for atopic dermatitis) with Astria Therapeutics in October 2023. In January 2025, Astria announced the initiation of a Phase-1 clinical trial of STAR0310, a potential best-in-class OX40 antagonist for the treatment of Atopic Dermatitis. Glenmark received €20.8 million for the upfront payment, plus development, regulatory, and sales milestone payments, and tiered royalties on global sales.
